Loading
NASDAQHealthcareDrug Manufacturers - General
Latest quote
$7.38
−$0.12 · -1.60%
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Regular session
$7.38
−$0.12 · -1.60%
Regular session · ET · Market data may be delayed.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Day range
Current $7.38
52-week range
Current $7.38
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
90
Deep Value
Sentiment
59
Mixed
Risk
43
Elevated Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Day range
Current $7.38
52-week range
Current $7.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.23B EUR | 7.21B EUR | 6.59B EUR | 6.06B EUR | 4.93B EUR |
| Cost of goods sold | 4.65B EUR | 4.42B EUR | 4.11B EUR | 3.85B EUR | 2.97B EUR |
| Gross profit | 2.58B EUR | 2.79B EUR | 2.48B EUR | 2.21B EUR | 1.96B EUR |
| Research and development | 358.28M EUR | 384.04M EUR | 395.28M EUR | 361.14M EUR | 354.88M EUR |
| Selling, general, and administrative | 1.02B EUR | 1.14B EUR | 1.27B EUR | 1.11B EUR | 1.06B EUR |
| Operating expenses | 1.39B EUR | 1.6B EUR | 1.7B EUR | 1.43B EUR | 1.37B EUR |
| Interest income | 32.66M EUR | 48.05M EUR | 62.43M EUR | 33.86M EUR | 11.55M EUR |
| Interest expense | 600.33M EUR | 773.16M EUR | 516.06M EUR | 444.54M EUR | 233.81M EUR |
| Depreciation and amortization | 432.24M EUR | 437.9M EUR | 446.42M EUR | 410.98M EUR | 359.77M EUR |
| Operating income | 1.19B EUR | 1.19B EUR | 782.32M EUR | 782.44M EUR | 595.06M EUR |
| Net income | 386.13M EUR | 156.92M EUR | 42.32M EUR | 185.04M EUR | 188.73M EUR |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB13.18M0.13%10.4B USD0.44%$199.9-1.69%
Brandes International ETFBINV6.91M1.32%523.76M USD0.70%$43.09+0.13%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.67M0.10%2.69B USD0.20%$65.47-1.40%
Brandes U.S. Small-Mid Cap Value ETFBSMC2.58M1.55%166.02M USD0.70%$37.91+0.01%
State Street SPDR Portfolio Developed World ex-US ETFSPDW2.34M0.01%41.32B USD0.03%$49.5499-0.80%
Capital Group International Core Equity ETFCGIC907.76K0.03%2.62B USD0.54%$35.455-1.02%
ActivePassive International Equity ETFAPIE212.03K0.02%1.17B USD0.45%$38.2357-0.89%
Invesco NASDAQ Future Gen 200 ETFQQQS116.54K0.51%22.96M USD0.20%$41.505-1.24%iShares Biotechnology ETFIBBBrandes International ETFBINVState Street SPDR S&P Kensho New Economies Composite ETFKOMPBrandes U.S. Small-Mid Cap Value ETFBSMCState Street SPDR Portfolio Developed World ex-US ETFSPDWCapital Group International Core Equity ETFCGICActivePassive International Equity ETFAPIEInvesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
